GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (ASX:NEU) » Definitions » Deferred Policy Acquisition Costs

Neuren Pharmaceuticals (ASX:NEU) Deferred Policy Acquisition Costs


View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Neuren Pharmaceuticals Business Description

Traded in Other Exchanges
Address
697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.